Publications by authors named "Katsuya Takagaki"
Nihon Yakurigaku Zasshi
November 2024
Article Synopsis
- Futibatinib, a new FGFR inhibitor developed by Taiho Pharmaceutical, was approved in Japan in June 2023 for treating inoperable biliary tract cancer with specific genetic changes after prior chemotherapy.
- This drug works by irreversibly binding to the FGFR receptor, inhibiting cancer cell growth more effectively than earlier FGFR inhibitors.
- In clinical studies, futibatinib demonstrated a 41.7% overall response rate in patients with certain types of bile duct cancer, showing a good safety profile and the potential to treat more cancer types in the future.*
